Plant‐Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease

Production and evaluation of monoclonal antibodies (MAbs) produced in plants to combat infectious diseases (IDs) has been ongoing for almost 20 years (1). With the recent FDA approval of the first plant‐derived biologic (2), development of rapid manufacturing technology (3), and the capability of producing MAbs with homogenous mammalian glycosylation (4), a wave of infectious disease (and other) MAbs that are plant‐derived are expected to enter clinical trials in the next several years. This review is intended to summarize the results of research on plant‐derived MAbs to infectious pathogens that have completed animal or clinical studies.